RxMP Therapeutics Inc.

RxMP Therapeutics is developing novel systemically delivered hemostatic agents composed of red blood cell membrane particles (RMPs). These RMPs are designed to arrest or prevent excessive bleeding, thereby improving health care outcomes and costs and reducing the need for transfused blood.